Nasdaq

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from ...
Business Wire

Checkpoint Systems Expands Health and Beauty RFID Label Portfolio For Improved Merchandise Visibility

THOROFARE, N.J.--(BUSINESS WIRE)--Checkpoint Systems, Inc. (NYSE:CKP), a leading global supplier of merchandise availability solutions for the retail industry, today announced that it has expanded its ...
Stockhouse

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 ...
FoodNavigator

Roadmap navigates FDA label changes

Food Label Compass, a joint project by FoodMinds, Nutrition Impact and EAS Consulting Group, helps food firms navigate sweeping changes to US labeling requirements. The US Food and Drug Administration ...